Conservative Treatment
Abstract
No abstract available.
Image: Cardarelli Hospital. Naples, Italy.
Downloads
References
Yeo CJ. Pancreatic cancer symposium. J Am Coll Surg 1998; 187:429-42.
Warshaw AL, Castillo CFD. Pancreatic adenenocarcinoma. New Engl J Med 1992; 326:455-65.
Moossa AR, Gamagami RA. Diagnosis and staging of pancreatic neoplasms. Surg Clin North Am 1995; 75:781-890.
Lillemoe KD. Current management of pancreatic carcinoma. Ann Surg 1995; 221:133-48.
Bramhall SR, Allum WH ,Jones AG, Allwood A, Cummins C, Neoptolemos JP. Incidence treatment and survival in 13560 patients with pancreatic cancer: an epidemiological study in the West Midlands. Br J Surg 1995; 82:111-5.
Beger HG, Link KH, Poch B, Gansauge F. Pancreatic cancer recent progress in diagnosis and treatment. In: Neoptolemos JP, Lemoine NR, eds. Pancreatic Cancer: Molecular and Clinical Advances. Oxford: Blackwell Science Ltd, 1996: 227-35.
Livingston EH, Welton MI, Reber HA. Surgical treatment of pancreatic cancer. The United States experience. Int J Pancreatol1991; 9:153-7.
Taylor I. Should further studies of chemotherapy be carried out in pancreatic cancer? Eur J Cancer 1993; 29:1076-8.
Moore M. Activity of gemcitabine in patients with pancreatic adenocarcinoma. Cancer 1996; 78 (Suppl. 1): 633-6.
Ahlgren JD. Chemotherapy for pancreatic adenocarcinoma. Cancer 1996; 78:655-63.
Mallinson CN, Rake MO, Cocking JB, Fox CA, Cwynarski MT, Diffey BL, et al. Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial. Br Med J 1980; 281:1589-91.
Arbuck SG. Chemotherapy for pancreatic cancer. Ballieres Clin Gastroenterol 1990; 4:953-68.
Bkkevold KE. Chemotherapy of unresectable pancreatic cancer. In: Beger HG, Warshaw AL, Russell RCG, Bucher M, Carr-Locke D, Neoptolemos JP, Sarr MG, eds. The Pancreas. Oxford: Blackwell Science Ltd, 1998: 1120-38.
Rothenberg ML, Abbruzese JL, Moore MJ, Portenoy RK, Robertson JM, Wanebo HG. A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer 1996; 78:627-32.
Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, et al. Phase II trial of gemcitabine (2’,2’-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994; 12:29 34.
Carmichael J, Fink U, Russell RC, Spittle MF, Harris AL, Spiessi G, Blatter J. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996; 73:101-5.
Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA 3rd, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996; 7:347-53.
Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-13.
Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1994; 12:1821-6.
Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP. Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994; 86:1530-3.
Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991; 51:6110-7.
Ghandi V, Plunkett W. Modulatory activity of 2’-2’deoxycytidine on the phosphorilation and cytotoxicity of arabinosyl nucleotides. Cancer Res 1990; 50:3675-80.
Hermanek P, Sobin LH, eds. UICC TNM classification of malignant tumours. 4th ed. Berlin: Springer-Verlag, 1987.
Theodors A, Bukowski RM, Hewlett JS, Livingston RB, Weick JK. Intermittent regional infusion of chemotherapy for pancreatic adenocarcinoma. Phase I and II pilot study. Am J Clin Oncol 1982; 5:555-8.
Zanon C, Alabiso O, Grosso M, Buosi R, Chiappino I, Clara R, et al. Intra-arterial continuous infusion for treatment of pancreatic and biliary tract cancer. Int J Pancreatol 2000; 27:225-33.
Zanon C, Grosso M, Zanon E, Veltri A, Alabiso O, Bazzan M, et al. Transaxillary access to perform hepatic artery infusion (HAI) for secondary or primitive hepatic tumors. Minerva Chir 1996; 51:755-8.
Grosso M, Zanon C, Zanon E, Corsico M, Gazzera C, Mancini A, Fava C. The percutaneous placement of intra-arterial catheters with "reservoirs" for subcutaneous infusion. The technic and preliminary results. Radiol Med 1997; 94:226-32.
Blackstock AW, Bernard SA, Richards F, Eagle KS, Case LD, Poole ME, et al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 1999; 17:2208-12.
McGinn CJ, Smith DC, Szarka CE. A phase I study of gemcitabine in combination with radiation therapy in patients with localized unresectable pancreatic cancer. Proc Am Soc Oncol 1998:264a.
Van Riel JM, Giaccone G, Pinedo HM. Pancreaticobiliary cancer: the future aspects of medical oncology. Ann Oncol 1999; 10 (Suppl. 4):296-9.
Carter G, Gilbert C, Lemoine NR. Effect of antisense oligonucleotides targeting K-ras expression in pancreatic cancer cell lines. Int J Oncol 1995; 6:1105-12.
Searle PF, Green NK, Young L. Gene-tranfer therapy and pancreatic Cancer. In: Neoptolemos JP, Lemoine NR, eds. Pancreatic Cancer. Molecular and Clinical Advances. Blackwell Science 1998.
Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 1990; 82:4-6.
Boehm T, Folkman J, Browder T, O’Relly MS. Antiangiogenic therapy of sperimental cancer does not induce acquired drug resistance. Nature 1997; 390:404-7.
Nelson NJ. Inhibitors of angiogenesis enter phase III testing. J Natl Cancer Inst 1998; 90:960-3.
Bramhall SR. The matrix metalloproteinases and their inhibitorsin pancreatic cancer. Int J Pancreatol 1997; 21:1-12.
Rosemurgy A, Harris J, Langleben A. Marimastat a novel metalloproteinase inhibitor in patients with advanced carcinoma of the pancreas. Proc Am Soc Clin Oncol 1996: A207.
Copyright (c) 2000 Pier Giorgio Rabitti, Domenico Germano
This work is licensed under a Creative Commons Attribution 4.0 International License.
As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.